Same Drug Class

Ipilimumab vs Pembrolizumab

Ipilimumab vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Ipilimumab and Pembrolizumab.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Pembrolizumab — 26 days.

Chemical Properties

Type: Ipilimumab — Antibody; Pembrolizumab — Antibody.